Mendelian randomization and bioinformatics analysis of the disulfidoptosis core gene SLC7A11 in clear cell renal cell carcinoma
10.3969/j.issn.1009-8291.2024.05.017
- VernacularTitle:肾透明细胞癌中双硫死亡核心基因SLC7A11的孟德尔随机化及生物信息学分析
- Author:
Zifeng LI
1
;
Bohong CHEN
1
;
Haoxiang HUANG
1
;
Cong FENG
1
;
Jin ZENG
1
;
Wei CHEN
1
;
Dapeng WU
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
- Publication Type:Journal Article
- Keywords:
solute carrier family 7 member 11 (SLC7A11);
clear cell renal cell carcinoma;
bioinformation analysis;
mendelian randomization;
biomarker;
therapeutic target
- From:
Journal of Modern Urology
2024;29(5):459-465
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the role of solute carrier family 7 member 11 (SLC7A11) in the pathogenesis and progression of clear cell renal cell carcinoma (ccRCC) and its prognostic significance. 【Methods】 Mendelian randomization analysis was employed to identify genes causally associated with the risk of ccRCC.The expression patterns and prognostic relevance of SLC7A11 were assessed using RNA sequencing data and clinical information obtained from the UCSC Xena pan-cancer cohort.Gene set enrichment analysis (GSEA) was conducted using data from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) dataset (training set).A prognostic model based on SLC7A11 was then developed using stepwise Cox regression and validated externally in the E-MTAB-1980 cohort (validation set) . 【Results】 Elevated level of SLC7A11 was associated with an increased risk of ccRCC (HR=1.27, 95%CI: 1.15-1.40, P<0.001).SLC7A11 was overexpressed in various tumors and correlated with higher T stage and poorer survival (P<0.05).GSEA demonstrated that SLC7A11 was enriched in pathways related to proliferation and metastasis, including E2F and epithelial-to-mesenchymal transition signaling pathways.Moreover, the SLC7A11 prognostic model exhibited robust predictive performance in both the training set (1-, 3-, and 5-year AUC=0.78, 0.73, 0.71, respectively) and the external validation set (1-, 3-, and 5-year AUC=0.70, 0.71, 0.72, respectively). 【Conclusion】 SLC7A11 can be a potential biomarker and therapeutic target for ccRCC, offering novel perspectives for precision medicine.
